Rallybio Announces Retirement of Jeffrey Fryer, CPA, Chief Money Officer

–Corporation initiates an external research for its subsequent Chief Economical Officer–

NEW HAVEN, Conn., June 02, 2022–(Small business WIRE)–Rallybio Corporation (Nasdaq: RLYB), a clinical-phase biotechnology enterprise dedicated to determining and accelerating the advancement of everyday living-reworking therapies for individuals with critical and uncommon health conditions, now announced that Jeffrey Fryer, CPA, will retire from his situation as Chief Financial Officer (CFO). Mr. Fryer will go on to serve as Rallybio’s CFO till a new CFO has been appointed and will retire from the Firm pursuing a transition interval. Rallybio has initiated an exterior lookup to identify its subsequent CFO.

“On behalf of the Board of Administrators, co-founder Steve Uden, and the Rallybio team, I would like to thank Jeff for his devotion and contributions around the previous four several years in aiding to make, create and remodel Rallybio into a publicly traded firm. He has been these types of a excellent friend, colleague and valued counselor to both equally Steve and me. We enjoy his leadership and partnership in executing our eyesight of a uncommon sickness corporation as a co-founder of Rallybio, and desire him all the most effective.” said Martin Mackay, Ph.D., Chief Government Officer of Rallybio.

Mr. Fryer commented, “It has been an honor and privilege to function with my co-founders Martin and Steve, and it has been a extremely rewarding expertise doing the job with Rallybio’s devoted and proficient group about the past four many years. With a developing pipeline and our potent money situation, I believe that that now is the appropriate time for me to retire from the Firm and to pursue a few other ambitions that I have. I am completely committed to ensuring a smooth transition and glimpse forward to next the continued achievement of the Rallybio team.”

About Rallybio

Rallybio is a scientific-phase biotechnology business dedicated to pinpointing and accelerating the development of existence-transforming therapies for individuals with intense and rare diseases. Due to the fact its start in January 2018, Rallybio has constructed a portfolio of promising product or service candidates, which are now in advancement to address uncommon ailments in the locations of hematology, immuno-inflammation, maternal fetal health, and metabolic problems. The Company’s mission is being advanced by a group of remarkably seasoned biopharma sector leaders with substantial study, enhancement, and scarce illness knowledge. Rallybio is headquartered in New Haven, Connecticut, with an extra facility at the College of Connecticut’s Technologies Incubation Software in Farmington, Connecticut. For extra info, you should go to www.rallybio.com.

Ahead-Wanting Statements

This press release contains ahead-searching statements that are based on our management’s beliefs and assumptions and on at present offered data. In some conditions, ahead-on the lookout statements can be discovered by phrases such as “may possibly,” “will,” “should,” “anticipate,” “program,” “foresee,” “could,” “intend,” “focus on,” “task,” “ponder,” “believe,” “estimate,” “forecast,” “opportunity” or “keep on” or the unfavorable of these terms or other very similar expressions, even though not all ahead-seeking statements consist of these words and phrases. Forward-hunting statements in this press launch include things like, but are not constrained to, statements concerning the timing of appointing a new Main Financial Officer, and the size of an govt transition period of time. The forward-searching statements in this press release are only predictions and are centered largely on management’s existing anticipations and projections about future functions and fiscal trends that administration thinks could impact Rallybio’s business enterprise, economic affliction and outcomes of operations. These forward-seeking statements communicate only as of the day of this push launch and are matter to a selection of recognized and not known hazards, uncertainties and assumptions, including, but not minimal to, our ability to correctly initiate and conduct our prepared clinical trials, like the FNAIT natural background review, and the Stage 1 and 1b clinical trials for RLYB212 and the Phase 1 examine for RLYB116, and complete these clinical trials and receive effects on our predicted timelines, or at all, no matter if our hard cash assets will be ample to fund our functioning expenses and funds expenditure needs and no matter whether we will be successful boosting more money, our potential to determine new item candidates and efficiently acquire this kind of solution candidates from 3rd get-togethers, our means to combine RLYB331 into our pipeline, level of competition from other biotechnology and pharmaceutical firms, and people risks and uncertainties explained in Rallybio’s filings with the U.S. Securities and Exchange Commission (SEC), like Rallybio’s Quarterly Report on Variety 10-Q for the period finished March 31, 2022, and subsequent filings with the SEC. The gatherings and circumstances mirrored in our forward-hunting statements may possibly not be obtained or take place and genuine upcoming benefits, amounts of activity, functionality and activities and conditions could differ materially from people projected in the forward-looking statements. Apart from as demanded by relevant law, we are not obligated to publicly update or revise any ahead-on the lookout statements contained in this push launch, no matter if as a final result of any new information and facts, upcoming gatherings, changed situation or if not.

Watch resource model on businesswire.com: https://www.businesswire.com/news/home/20220601005884/en/


Steven Tuch
Head of Corporate Growth
[email protected]

Ami Bavishi
Head of Trader Relations and Communications
[email protected]

Hannah Deresiewicz
Stern Trader Relations, Inc.
[email protected]

Tara DiMilia
[email protected]